Library · Digestive & liver · Treatment of type 2 diabetes and obesity
Ecnoglutide (XW003)
XW003, XW-003
Long-acting GLP-1 receptor agonist (XW003) from Sciwind Biosciences, optimized for potency and manufacturing cost. Trials show meaningful weight loss and HbA1c reduction in type 2 diabetes and obesity.
Research score 80/100. Reference only, not a dose.
- GLP-1 Agonist
- Blood Sugar Control
- Appetite Suppression
- Metabolic Enhancement
- Weight Loss
- US status
- Research Chemical
- Approval
- Phase 3 Clinical Trial
- Evidence
- Phase 3 trials ongoing (SLIMMER, T2DM). Shown superiority to placebo and comparable safety to dulaglutide.
- Research score
- 80 / 100
- Indication
- Type 2 Diabetes Mellitus
- Origin
- China
- Source category
- Digestive System
- Status group
- Research chemical
Mechanism
Selectively binds GLP-1 receptors on pancreatic beta cells, raising cAMP for glucose-dependent insulin release; structural changes resist DPP-4 breakdown for a longer half-life, while hypothalamic receptor activation curbs appetite and slows gastric emptying.
Safety file
Consistent with other GLP-1 drugs; GI effects (nausea, diarrhea) are most common, with low trial discontinuation rates.
- Nausea
- Vomiting
- Diarrhea
- Injection site reactions
- Decreased appetite